RU2004129285A - Производные тиазола в качестве антагонистов рецептора npy - Google Patents
Производные тиазола в качестве антагонистов рецептора npy Download PDFInfo
- Publication number
- RU2004129285A RU2004129285A RU2004129285/04A RU2004129285A RU2004129285A RU 2004129285 A RU2004129285 A RU 2004129285A RU 2004129285/04 A RU2004129285/04 A RU 2004129285/04A RU 2004129285 A RU2004129285 A RU 2004129285A RU 2004129285 A RU2004129285 A RU 2004129285A
- Authority
- RU
- Russia
- Prior art keywords
- ylamino
- thiazol
- methylbenzoyl
- propyl
- methyl
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000007979 thiazole derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 229940086609 Lipase inhibitor Drugs 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 3
- 229960001243 orlistat Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- OJBJPKNOXBHZGJ-UHFFFAOYSA-N 2-chloro-n-[3-[[4-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]-5-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=CC=CC=C1C(=O)C1=CSC(NCCCNS(=O)(=O)C=2C(=CC=C(C=2)C(F)(F)F)Cl)=N1 OJBJPKNOXBHZGJ-UHFFFAOYSA-N 0.000 claims 1
- VSKXSADWIKAJOW-UHFFFAOYSA-N 2-chloro-n-[3-[[5-(2-chlorobenzoyl)-1,3-thiazol-2-yl]amino]propyl]-5-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=C(Cl)C(S(=O)(=O)NCCCNC=2SC(=CN=2)C(=O)C=2C(=CC=CC=2)Cl)=C1 VSKXSADWIKAJOW-UHFFFAOYSA-N 0.000 claims 1
- MOAWCMYHSCPOHS-UHFFFAOYSA-N 2-chloro-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCNS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1Cl MOAWCMYHSCPOHS-UHFFFAOYSA-N 0.000 claims 1
- WSZRBYPVRMTROP-UHFFFAOYSA-N 2-chloro-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]-5-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCNS(=O)(=O)C1=CC(C(F)(F)F)=CC=C1Cl WSZRBYPVRMTROP-UHFFFAOYSA-N 0.000 claims 1
- DOAQWUHLLDBVCS-UHFFFAOYSA-N 2-chloro-n-[5-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]pentyl]-5-(trifluoromethyl)benzenesulfonamide Chemical compound CC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCCCNS(=O)(=O)C1=CC(C(F)(F)F)=CC=C1Cl DOAQWUHLLDBVCS-UHFFFAOYSA-N 0.000 claims 1
- JFZKIMSEVKSNHD-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[3-[[4-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NCCCNC1=NC(C(=O)C=2C(=CC=CC=2)C)=CS1 JFZKIMSEVKSNHD-UHFFFAOYSA-N 0.000 claims 1
- BFGZPYGHAVNFFS-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NCCCNC1=NC=C(C(=O)C=2C(=CC=CC=2)C)S1 BFGZPYGHAVNFFS-UHFFFAOYSA-N 0.000 claims 1
- QPKQMQKFALBADC-UHFFFAOYSA-N 5-chloro-n-methyl-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]thiophene-2-sulfonamide Chemical compound C=1C=C(Cl)SC=1S(=O)(=O)N(C)CCCNC(S1)=NC=C1C(=O)C1=CC=CC=C1C QPKQMQKFALBADC-UHFFFAOYSA-N 0.000 claims 1
- BEAINTSVUWXBAX-UHFFFAOYSA-N CC1=C(C(=O)C2=CN=C(S2)NCCCC2=C(SC(=C2)Cl)S(=O)(=O)N)C=CC=C1 Chemical compound CC1=C(C(=O)C2=CN=C(S2)NCCCC2=C(SC(=C2)Cl)S(=O)(=O)N)C=CC=C1 BEAINTSVUWXBAX-UHFFFAOYSA-N 0.000 claims 1
- BBZFDKLYASESAQ-UHFFFAOYSA-N CC1=C(C(=O)C2=CN=C(S2)NCCCC2=C(SC=C2)S(=O)(=O)N)C=CC=C1 Chemical compound CC1=C(C(=O)C2=CN=C(S2)NCCCC2=C(SC=C2)S(=O)(=O)N)C=CC=C1 BBZFDKLYASESAQ-UHFFFAOYSA-N 0.000 claims 1
- IPEAWOUNHJWWOQ-UHFFFAOYSA-N ClC1=C(C(=O)C2=CN=C(S2)NCCCC2=C(SC=C2)S(=O)(=O)N)C=CC=C1 Chemical compound ClC1=C(C(=O)C2=CN=C(S2)NCCCC2=C(SC=C2)S(=O)(=O)N)C=CC=C1 IPEAWOUNHJWWOQ-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- -1 methyl- {3- [5- (2-methylbenzoyl) thiazol-2-ylamino] propyl} Chemical class 0.000 claims 1
- DWXOPSSXKDXLTE-UHFFFAOYSA-N n-[3-[[5-(2-chlorobenzoyl)-1,3-thiazol-2-yl]amino]propyl]-2-methoxy-5-methylbenzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NCCCNC1=NC=C(C(=O)C=2C(=CC=CC=2)Cl)S1 DWXOPSSXKDXLTE-UHFFFAOYSA-N 0.000 claims 1
- CSNICAGFSAQDIK-UHFFFAOYSA-N n-[4-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]butyl]thiophene-2-sulfonamide Chemical compound CC1=CC=CC=C1C(=O)C(S1)=CN=C1NCCCCNS(=O)(=O)C1=CC=CS1 CSNICAGFSAQDIK-UHFFFAOYSA-N 0.000 claims 1
- KYZCONUNJLEHBB-UHFFFAOYSA-N n-[5-[[5-(2-chlorobenzoyl)-1,3-thiazol-2-yl]amino]pentyl]-2-fluorobenzenesulfonamide Chemical compound FC1=CC=CC=C1S(=O)(=O)NCCCCCNC1=NC=C(C(=O)C=2C(=CC=CC=2)Cl)S1 KYZCONUNJLEHBB-UHFFFAOYSA-N 0.000 claims 1
- KITOQPGNBHIXGH-UHFFFAOYSA-N n-[5-[[5-(2-chlorobenzoyl)-1,3-thiazol-2-yl]amino]pentyl]-2-methoxy-5-methylbenzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NCCCCCNC1=NC=C(C(=O)C=2C(=CC=CC=2)Cl)S1 KITOQPGNBHIXGH-UHFFFAOYSA-N 0.000 claims 1
- XJTXAAPTCQPFDF-UHFFFAOYSA-N n-[5-[[5-(2-chlorobenzoyl)-1,3-thiazol-2-yl]amino]pentyl]-2-methylbenzenesulfonamide Chemical compound CC1=CC=CC=C1S(=O)(=O)NCCCCCNC1=NC=C(C(=O)C=2C(=CC=CC=2)Cl)S1 XJTXAAPTCQPFDF-UHFFFAOYSA-N 0.000 claims 1
- WTDLBONHJHWXJS-UHFFFAOYSA-N n-methyl-n-[3-[[5-(2-methylbenzoyl)-1,3-thiazol-2-yl]amino]propyl]-4-nitrobenzenesulfonamide Chemical compound C=1C=C([N+]([O-])=O)C=CC=1S(=O)(=O)N(C)CCCNC(S1)=NC=C1C(=O)C1=CC=CC=C1C WTDLBONHJHWXJS-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02004296.6 | 2002-02-28 | ||
| EP02004296 | 2002-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004129285A true RU2004129285A (ru) | 2005-10-27 |
Family
ID=27763338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004129285/04A RU2004129285A (ru) | 2002-02-28 | 2003-02-19 | Производные тиазола в качестве антагонистов рецептора npy |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6686381B2 (enExample) |
| EP (1) | EP1480976B1 (enExample) |
| JP (1) | JP2005526732A (enExample) |
| KR (1) | KR100611854B1 (enExample) |
| CN (1) | CN100363362C (enExample) |
| AR (1) | AR038704A1 (enExample) |
| AT (1) | ATE373654T1 (enExample) |
| AU (1) | AU2003210305B2 (enExample) |
| BR (1) | BR0308108A (enExample) |
| CA (1) | CA2475299A1 (enExample) |
| DE (1) | DE60316411T2 (enExample) |
| ES (1) | ES2292992T3 (enExample) |
| GT (1) | GT200300045A (enExample) |
| MX (1) | MXPA04008379A (enExample) |
| PA (1) | PA8567301A1 (enExample) |
| PE (1) | PE20030930A1 (enExample) |
| PL (1) | PL372463A1 (enExample) |
| RU (1) | RU2004129285A (enExample) |
| TW (1) | TW200403995A (enExample) |
| UY (1) | UY27689A1 (enExample) |
| WO (1) | WO2003072577A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| CA2533464A1 (en) * | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | Thiazole derivatives as npy antagonists |
| CN100422179C (zh) | 2003-08-12 | 2008-10-01 | 霍夫曼-拉罗奇有限公司 | 2-氨基-5-苯甲酰基噻唑npy拮抗剂 |
| AU2004299198A1 (en) * | 2003-12-08 | 2005-06-30 | F. Hoffmann-La Roche Ag | Novel thiazole derivates |
| JP4879165B2 (ja) * | 2004-04-20 | 2012-02-22 | トランス テック ファーマ，インコーポレイテッド | メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体 |
| FR2884516B1 (fr) * | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| EP1981884B1 (en) * | 2006-01-18 | 2012-06-13 | Amgen, Inc | Thiazole compounds as protein kinase b (pkb) inhibitors |
| WO2010098298A1 (ja) * | 2009-02-27 | 2010-09-02 | 塩野義製薬株式会社 | 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物 |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| JP2021512105A (ja) | 2018-01-31 | 2021-05-13 | デシフェラ・ファーマシューティカルズ，エルエルシー | 消化管間質腫瘍の治療のための併用療法 |
| CN118903436A (zh) | 2018-01-31 | 2024-11-08 | 德西费拉制药有限责任公司 | 治疗肥大细胞增多症的组合疗法 |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| NZ784949A (en) | 2019-08-12 | 2025-09-26 | Deciphera Pharmaceuticals Llc | Ripretinib for treating gastrointestinal stromal tumors |
| FI4084778T3 (fi) | 2019-12-30 | 2023-12-18 | Deciphera Pharmaceuticals Llc | Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi |
| SMT202400484T1 (it) | 2019-12-30 | 2025-01-14 | Deciphera Pharmaceuticals Llc | Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| AUPN163795A0 (en) | 1995-03-10 | 1995-04-06 | DIPNALL, David | A device for extracting energy from moving water particles |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
| EP1105123B1 (en) | 1998-08-14 | 2004-04-07 | F.Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors and chitosan |
| PT1105122E (pt) | 1998-08-14 | 2005-08-31 | Hoffmann La Roche | Composicoes farmaceuticas que contem inibidores de lipase |
| US20010039275A1 (en) * | 2000-02-04 | 2001-11-08 | Bowler Andrew Neil | Use of 2,4-diaminothiazole derivatives |
| WO2001064675A1 (en) * | 2000-03-03 | 2001-09-07 | Novartis Ag | Condensed thiazolamines and their use as neuropeptide y5 antagonists |
| JP2004538315A (ja) * | 2001-08-03 | 2004-12-24 | ノボ・ノルデイスク・エー／エス | 新規の２，４−ジアミノチアゾール誘導体 |
-
2003
- 2003-02-19 DE DE60316411T patent/DE60316411T2/de not_active Expired - Fee Related
- 2003-02-19 AT AT03742945T patent/ATE373654T1/de not_active IP Right Cessation
- 2003-02-19 AU AU2003210305A patent/AU2003210305B2/en not_active Ceased
- 2003-02-19 WO PCT/EP2003/001667 patent/WO2003072577A1/en not_active Ceased
- 2003-02-19 BR BR0308108-7A patent/BR0308108A/pt not_active IP Right Cessation
- 2003-02-19 JP JP2003571283A patent/JP2005526732A/ja active Pending
- 2003-02-19 KR KR1020047013315A patent/KR100611854B1/ko not_active Expired - Fee Related
- 2003-02-19 RU RU2004129285/04A patent/RU2004129285A/ru not_active Application Discontinuation
- 2003-02-19 CA CA002475299A patent/CA2475299A1/en not_active Abandoned
- 2003-02-19 EP EP03742945A patent/EP1480976B1/en not_active Expired - Lifetime
- 2003-02-19 CN CNB03804823XA patent/CN100363362C/zh not_active Expired - Fee Related
- 2003-02-19 MX MXPA04008379A patent/MXPA04008379A/es active IP Right Grant
- 2003-02-19 PL PL03372463A patent/PL372463A1/xx not_active Application Discontinuation
- 2003-02-19 ES ES03742945T patent/ES2292992T3/es not_active Expired - Lifetime
- 2003-02-25 PA PA20038567301A patent/PA8567301A1/es unknown
- 2003-02-25 PE PE2003000182A patent/PE20030930A1/es not_active Application Discontinuation
- 2003-02-26 AR ARP030100627A patent/AR038704A1/es not_active Application Discontinuation
- 2003-02-26 TW TW092104045A patent/TW200403995A/zh unknown
- 2003-02-26 GT GT200300045A patent/GT200300045A/es unknown
- 2003-02-26 US US10/374,573 patent/US6686381B2/en not_active Expired - Fee Related
- 2003-02-27 UY UY27689A patent/UY27689A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005526732A (ja) | 2005-09-08 |
| EP1480976A1 (en) | 2004-12-01 |
| US6686381B2 (en) | 2004-02-03 |
| KR20040094735A (ko) | 2004-11-10 |
| AU2003210305A1 (en) | 2003-09-09 |
| ES2292992T3 (es) | 2008-03-16 |
| PL372463A1 (en) | 2005-07-25 |
| GT200300045A (es) | 2003-09-23 |
| DE60316411D1 (de) | 2007-10-31 |
| TW200403995A (en) | 2004-03-16 |
| CN100363362C (zh) | 2008-01-23 |
| PA8567301A1 (es) | 2004-02-07 |
| KR100611854B1 (ko) | 2006-08-11 |
| PE20030930A1 (es) | 2003-11-08 |
| UY27689A1 (es) | 2003-08-29 |
| AU2003210305B2 (en) | 2006-07-06 |
| AR038704A1 (es) | 2005-01-26 |
| US20030225141A1 (en) | 2003-12-04 |
| EP1480976B1 (en) | 2007-09-19 |
| WO2003072577A1 (en) | 2003-09-04 |
| CN1639158A (zh) | 2005-07-13 |
| MXPA04008379A (es) | 2004-11-26 |
| DE60316411T2 (de) | 2008-06-12 |
| BR0308108A (pt) | 2004-12-07 |
| CA2475299A1 (en) | 2003-09-04 |
| ATE373654T1 (de) | 2007-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004129285A (ru) | Производные тиазола в качестве антагонистов рецептора npy | |
| KR101245062B1 (ko) | 칼슘이온-방출-활성화-칼슘이온 채널을 조절하는 방법 | |
| ES2534392T3 (es) | Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso | |
| JP5115474B2 (ja) | 消化管潰瘍治療又は予防薬 | |
| KR101678255B1 (ko) | 치환 아미드 화합물 | |
| AU2007322116B2 (en) | Cyclohexenyl-aryl compounds for inflammation and immune-related uses | |
| JP2005526732A5 (enExample) | ||
| RU2006105101A (ru) | Арилокси и арилалкиленокси замещенные имидазохинолины | |
| RU2005128190A (ru) | Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации | |
| JP2004534035A5 (enExample) | ||
| RU2008108984A (ru) | Терапевтический агент от диабета | |
| JP2013100376A (ja) | ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体 | |
| JP2007523905A5 (enExample) | ||
| RU2006134004A (ru) | Производные гетероариламинопиразола, пригодные для лечения диабета | |
| JP3555620B2 (ja) | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 | |
| JP2005525371A5 (enExample) | ||
| JP2019523237A (ja) | 乳酸脱水素酵素の阻害剤としての１ｈ−ピラゾール−１−イル−チアゾールおよびそれらの使用方法 | |
| KR20080034436A (ko) | 암 치료에 사용되는 티아졸 유도체 및 유사체 | |
| RU2015126293A (ru) | Производные тиазола в качестве ингибиторов тирозинкиназы брутона | |
| JP3591514B2 (ja) | 複素環誘導体 | |
| RU2006107444A (ru) | 2-амино-5-бензоилтиазолы в качестве антагонистов npy | |
| RU2005111983A (ru) | Производные 4-(фенил-пиперазинил-метил)бензамида и их применение для лечения боли или желудочно-кишечных расстройств | |
| JP2007532654A5 (enExample) | ||
| JP2007538102A5 (enExample) | ||
| JP2008115166A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20060714 |